

US - OSHA SAFETY DATA SHEET

Issue Date 15-Apr-2015 Revision Date 14-May-2020 Version 5

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier

Product Name IMOVAX® Rabies

Other means of identification

Product Information One vial of freeze-dried vaccine containing a single dose.

One sterile syringe containing diluent.

Synonyms Rabies Vaccine

Recommended use of the chemical and restrictions on use

Recommended Use Indicated for pre-exposure and post-exposure prophylaxis against rabies.

Uses advised against Not available.

Details of the supplier of the safety data sheet

Supplier Address Sanofi Pasteur 1 Discovery Drive Swiftwater, PA 18370

Phone: 1-800-822-2463 (1-800-VACCINE)

Emergency telephone number

24 Hour Emergency Phone 1-703-741-5970 / 1-800-424-9300 CCN # 2118 (CHEMTREC)

2. HAZARDS IDENTIFICATION

Classification

Health Hazards

Not classified.

Physical hazards

Not classified.

OSHA Regulatory Status

This product is a vaccine that is safe for consumers when used according to the label directions. Potential hazards that may occur if product is not used according to the consumer label are as follows throughout the sheet.

Label elements

Emergency Overview

Normal precautions common to safe manufacturing practice should be followed in handling and storage.

Appearance Freeze dried vaccine is Physical state Liquid after reconstitution Odor Not available.

creamy white to orange.

Liquid is pink to red after reconstitution.

Hazards not otherwise classified (HNOC)

Not classified as a hazardous substance.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Synonyms Not available.

Chemical Name	CAS No.	Weight-%
Rabies Virus	N/A	N/A
Water	7732-18-5	q.s. to 100

Note: Ingredients below reportable levels are not listed.

4. FIRST AID MEASURES

First aid measures

Eye contact In case of eye contact, immediately flush eyes with fresh water for at least 15 minutes while

holding the eyelids open. Remove contact lenses if worn. Get medical attention if irritation

persists.

Skin Contact In case of contact, remove contaminated clothing. Immediately flush skin with copious

amounts of water for at least 15 minutes. Obtain medical attention if skin reaction occurs.

Inhalation In case of inhalation, remove to fresh air. If breathing is difficult, administer oxygen. Seek

medical attention immediately.

Ingestion In case of accidental ingestion, wash out mouth with copious amounts of water. Seek

medical attention if needed. Do not induce vomiting unless directed by medical personnel.

Never give anything by mouth to an unconscious person.

Self-protection of the first aiderDo not use mouth-to-mouth method if victim ingested or inhaled the substance; give

artificial respiration with the aid of a pocket mask equipped with a one-way valve or other

proper respiratory medical device.

Most important symptoms and effects, both acute and delayed

Symptoms Common effects of the vaccine include the following: headache, nausea, abdominal pain,

muscle aches, and dizziness; local injection site reactions include pain, erythema, swelling

or itching.

Indication of any immediate medical attention and special treatment needed

Note to physiciansTreat symptomatically.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media None known.

Specific hazards arising from the chemical

Not available.

Hazardous combustion products Not available.

Explosion data

Sensitivity to Mechanical Impact Not available.
Sensitivity to Static Discharge None known.

Protective equipment and precautions for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full

protective gear.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Personal precautionsWear appropriate personal protective equipment (see Section 8).

Environmental precautions

Environmental precautions See Section 12 for additional ecological information.

Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Wipe up with absorbent material (e.g. cloth) for disposal. Area where spill occurred can be

cleaned with the regular cleaning materials designated for the area.

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities

Storage Conditions Store at 2° to 8°C (35° to 46°F). Do not freeze.

Incompatible materials Not available.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure GuidelinesThis product, as supplied, does not contain any hazardous materials with Occupational

Exposure Limits (OEL) established by the region specific regulatory bodies.

Appropriate engineering controls

Engineering Controls

Used as supplied, no special engineering controls are needed when administering the

vaccine.

Individual protection measures, such as personal protective equipment

Eye/face protection In laboratory or industrial settings, safety glasses with side shields are recommended.

Skin and body protection In laboratory or industrial settings, gloves and lab coats are recommended.

Respiratory protection Used as supplied, general room ventilation is acceptable and no special respiratory

protection is needed when administering the vaccine.

General Hygiene Considerations Always observe good personal hygiene measures, such as washing after handling the

material and before eating, drinking, and/or smoking. Routinely wash work clothing and

protective equipment.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state Solid

AppearanceFreeze driedOdorNot available.ColorCreamy white to orangeOdor thresholdNot available.

Property Values Remarks • Method

pH Not available.

Melting point/freezing point Not available.

Boiling point / boiling range
Flash point
Evaporation rate
Flammability (solid, gas)
Not available.
Not available.
Not available.

Flammability Limit in Air

Upper flammability limit: Not available. Lower flammability limit: Not available. Vapor pressure Not available. Vapor density Not available. **Specific Gravity** Not available. Water solubility Not available. Solubility in other solvents Not available. **Partition coefficient** Not available. **Autoignition temperature** Not available. **Decomposition temperature** Not available. Kinematic viscosity Not available. Dynamic viscosity Not available. **Explosive properties** Not available. Oxidizing properties Not available.

Other Information

Softening point
Molecular weight
VOC Content (%)
Density
Bulk density
Not available.
Not available.
Not available.
Not available.
Not available.

10. STABILITY AND REACTIVITY

Reactivity

Not reactive under normal conditions.

Chemical stability

Stable under normal conditions.

Possibility of Hazardous Reactions

None under normal handling.

Hazardous polymerization

Hazardous polymerization does not occur.

Conditions to avoid

Not available.

Incompatible materials

Not available.

Hazardous Decomposition Products

None under normal use conditions.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information No data available.

Inhalation No impact known or expected under normal use.

Eye contact No impact known or expected under normal use. .

Skin Contact No impact known or expected under normal use. .

Ingestion No impact known or expected under normal use. .

Information on toxicological effects

Symptoms Common effects of the vaccine include the following: headache, nausea, abdominal pain,

muscle aches, and dizziness; local injection site reactions include pain, erythema, swelling

or itching.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation
Serious eye damage/eye irritation
Irritation
Corrosivity
Sensitization
Germ cell mutagenicity
Carcinogenicity
Not available.

Reproductive toxicity

Animal reproduction studies have not been conducted with Imovax Rabies vaccine. It is

also not known whether Imovax Rabies vaccine can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. It is not known whether Imovax

Rabies vaccine is excreted in human milk.

Developmental Toxicity
Teratogenicity
STOT - single exposure
STOT - repeated exposure
Chronic toxicity
Subchronic toxicity
Not available.
Not available.
Not available.
Not available.
Not available.

Target Organ Effects
Neurological effects
Other adverse effects
Not available.
Not available.
Not available.
Not available.
Not available.
Not available.

12. ECOLOGICAL INFORMATION

Ecotoxicity

Not available.

Persistence and degradability

Not available.

Bioaccumulation

Not available.

Mobility

Not available.

Other adverse effects

Not available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes

Disposal should be in accordance with applicable regional, national and local laws and

regulations.

Contaminated packaging Disposal should be in accordance with applicable regional, national and local laws and

regulations.

US EPA Waste Number Not applicable.

California Hazardous Waste Codes Not applicable.

14	TR	ΔN	ISP		INFORMATION
	- 1 1 /	Δ I	101	\mathbf{v}	

DOT Not regulated.

TDG Not regulated.

MEX Not regulated.

ICAO (air) Not regulated.

IATA Not regulated.

IMDG Not regulated.

RID Not regulated.

ADR Not regulated.

ADN Not regulated.

15. REGULATORY INFORMATION

US Federal Regulations

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute health hazard No
Chronic Health Hazard No
Fire hazard No
Sudden release of pressure hazard No
Reactive Hazard No

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

US State Regulations

California Proposition 65

Component (Neomycin Sulfate, USP) is on Proposition 65 list; however, based on percentage of formulation it is not considered hazardous.

Component (Beta-propiolactone) is on Proposition 65 list; however, based on percentage of formulation it is not considered hazardous.

U.S. State Right-to-Know Regulations

This drug is regulated by the Food and Drug Administration and is therefore exempt from State Right-to-Know Regulations.

16. OTHER INFORMATION

Prepared By IES Engineers Issue Date 15-Apr-2015 Revision Date 14-May-2020

Revision Note Updated Sanofi Pasteur address, Symptoms, and Reproductive Toxicity. Revised by Sanofi

Pasteur.

Disclaimer

Sanofi Pasteur considers that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. The information contained herein is designated only as guidance for safe handling, storage and use of the substance and is not a specification nor does it guarantee any specific properties. Only competent personnel, within a controlled environment should handle all chemicals. Sanofi Pasteur cannot be held liable for any loss, injury or damage from contact with the product.

End of Safety Data Sheet
